NZ751010A - Gpr156 variants and uses thereof - Google Patents
Gpr156 variants and uses thereofInfo
- Publication number
- NZ751010A NZ751010A NZ751010A NZ75101017A NZ751010A NZ 751010 A NZ751010 A NZ 751010A NZ 751010 A NZ751010 A NZ 751010A NZ 75101017 A NZ75101017 A NZ 75101017A NZ 751010 A NZ751010 A NZ 751010A
- Authority
- NZ
- New Zealand
- Prior art keywords
- gpr156
- aspartic acid
- disclosure
- protein
- alterations
- Prior art date
Links
- 101150071692 Gpr156 gene Proteins 0.000 title 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 3
- 235000003704 aspartic acid Nutrition 0.000 abstract 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 208000020401 Depressive disease Diseases 0.000 abstract 2
- 101001039301 Homo sapiens Probable G-protein coupled receptor 156 Proteins 0.000 abstract 2
- 102100041015 Probable G-protein coupled receptor 156 Human genes 0.000 abstract 2
- 230000004075 alteration Effects 0.000 abstract 2
- 201000003104 endogenous depression Diseases 0.000 abstract 2
- 208000024714 major depressive disease Diseases 0.000 abstract 2
- 101100505306 Homo sapiens GPR156 gene Proteins 0.000 abstract 1
- 101000887490 Homo sapiens Guanine nucleotide-binding protein G(z) subunit alpha Proteins 0.000 abstract 1
- -1 cDNA Chemical class 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 abstract 1
- 102000052301 human GNAZ Human genes 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662367973P | 2016-07-28 | 2016-07-28 | |
| PCT/US2017/044321 WO2018022967A1 (en) | 2016-07-28 | 2017-07-28 | Gpr156 variants and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ751010A true NZ751010A (en) | 2024-11-29 |
Family
ID=59649989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ751010A NZ751010A (en) | 2016-07-28 | 2017-07-28 | Gpr156 variants and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10266582B2 (enExample) |
| EP (2) | EP4230648A3 (enExample) |
| JP (2) | JP7556688B2 (enExample) |
| KR (2) | KR102661616B1 (enExample) |
| CN (1) | CN109563516B (enExample) |
| AU (1) | AU2017302611B2 (enExample) |
| CA (1) | CA3032124A1 (enExample) |
| DK (1) | DK3491014T5 (enExample) |
| IL (1) | IL264473A (enExample) |
| MX (2) | MX2019001084A (enExample) |
| NZ (1) | NZ751010A (enExample) |
| SG (1) | SG11201900738YA (enExample) |
| WO (1) | WO2018022967A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4230648A3 (en) * | 2016-07-28 | 2023-10-18 | Regeneron Pharmaceuticals, Inc. | Gpr156 variants and uses thereof |
| SG11202001754RA (en) | 2017-09-06 | 2020-03-30 | Regeneron Pharma | Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof |
| PL3505157T3 (pl) | 2017-12-29 | 2022-04-11 | Celon Pharma S.A. | Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| AU2020209184A1 (en) * | 2019-01-17 | 2021-07-08 | Regeneron Pharmaceuticals, Inc. | A rodent model of mood disorders |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5294533A (en) | 1988-07-05 | 1994-03-15 | Baylor College Of Medicine | Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria |
| US5135917A (en) | 1990-07-12 | 1992-08-04 | Nova Pharmaceutical Corporation | Interleukin receptor expression inhibiting antisense oligonucleotides |
| US5271941A (en) | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
| US5786138A (en) | 1993-01-29 | 1998-07-28 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Hyperstabilizing antisense nucleic acid binding agents |
| DE69425890D1 (de) | 1993-06-04 | 2000-10-19 | Us Health | Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide |
| US5578716A (en) | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
| US5641754A (en) | 1994-01-10 | 1997-06-24 | The Board Of Regents Of The University Of Nebraska | Antisense oligonucleotide compositions for selectively killing cancer cells |
| JPH10503934A (ja) | 1994-08-09 | 1998-04-14 | ノバルティス アクチエンゲゼルシャフト | 抗腫瘍性アンチセンスオリゴヌクレオチド |
| US5856103A (en) | 1994-10-07 | 1999-01-05 | Board Of Regents The University Of Texas | Method for selectively ranking sequences for antisense targeting |
| US5994320A (en) | 1995-02-06 | 1999-11-30 | Regents Of The University Of Minnesota | Antisense oligonucleotides and methods for treating central nervous system tumors |
| IT1275862B1 (it) | 1995-03-03 | 1997-10-24 | Consiglio Nazionale Ricerche | Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento |
| US6040296A (en) | 1995-06-07 | 2000-03-21 | East Carolina University | Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation |
| WO1997014709A1 (en) | 1995-10-13 | 1997-04-24 | F. Hoffmann-La Roche Ag | Antisense oligomers |
| CA2236825A1 (en) | 1995-11-21 | 1997-05-29 | Icn Pharmaceuticals, Inc. | Inhibition of tumor growth by antisense oligonucleotides for il-8 and il-8 receptor |
| US5998602A (en) | 1996-02-15 | 1999-12-07 | The Cleveland Clinic Fouindation And Government | RNase L activators and antisense oligonucleotides effective to treat RSV infections |
| US5955590A (en) | 1996-07-15 | 1999-09-21 | Worcester Foundation For Biomedical Research | Conjugates of minor groove DNA binders with antisense oligonucleotides |
| US6046004A (en) | 1997-02-27 | 2000-04-04 | Lorne Park Research, Inc. | Solution hybridization of nucleic acids with antisense probes having modified backbones |
| JPH1142091A (ja) | 1997-07-25 | 1999-02-16 | Toagosei Co Ltd | アンチセンス核酸化合物 |
| US6046319A (en) | 1997-10-22 | 2000-04-04 | University Technologies International, Inc. | Antisense oligodeoxynucleotides regulating expression of TNF-α |
| US6551795B1 (en) | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| US6007995A (en) | 1998-06-26 | 1999-12-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of TNFR1 expression |
| US6013522A (en) | 1999-02-23 | 2000-01-11 | Isis Pharmaceuticals Inc. | Antisense inhibition of human Smad1 expression |
| US6025198A (en) | 1999-06-25 | 2000-02-15 | Isis Pharmaceuticals Inc. | Antisense modulation of Ship-2 expression |
| AU6343400A (en) * | 1999-07-09 | 2001-01-30 | Genaissance Pharmaceuticals, Inc. | Drug target isogenes: polymorphisms in the osteoclastogenesis inhibitory factor gene |
| US6033910A (en) | 1999-07-19 | 2000-03-07 | Isis Pharmaceuticals Inc. | Antisense inhibition of MAP kinase kinase 6 expression |
| AU2001255397A1 (en) * | 2000-04-18 | 2001-10-30 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the ugt1a1 gene |
| JP2006513702A (ja) | 2002-09-09 | 2006-04-27 | ヌラ インコーポレーティッド | Ｇタンパク質共役受容体およびその使用 |
| DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
| EP1745018A1 (en) * | 2004-04-29 | 2007-01-24 | Merck & Co., Inc. | Azetidine glycine transporter inhibitors |
| EP2091556B1 (en) | 2006-11-15 | 2018-07-25 | Omeros Corporation | Non-human animal comprising a mutation in the sreb2/gpr85 gene as animal model of metabolic disease |
| AU2013262709A1 (en) * | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating MECP2 expression |
| MY189533A (en) | 2012-05-25 | 2022-02-16 | Univ California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| AU2013355214B2 (en) | 2012-12-06 | 2017-06-15 | Sigma-Aldrich Co. Llc | Crispr-based genome modification and regulation |
| SG11201805112WA (en) * | 2015-12-21 | 2018-07-30 | Bayer Oy | A method of manufacturing a vaginal ring |
| EP4230648A3 (en) | 2016-07-28 | 2023-10-18 | Regeneron Pharmaceuticals, Inc. | Gpr156 variants and uses thereof |
-
2017
- 2017-07-28 EP EP23162215.0A patent/EP4230648A3/en not_active Withdrawn
- 2017-07-28 CN CN201780048589.4A patent/CN109563516B/zh active Active
- 2017-07-28 JP JP2019504021A patent/JP7556688B2/ja active Active
- 2017-07-28 AU AU2017302611A patent/AU2017302611B2/en active Active
- 2017-07-28 CA CA3032124A patent/CA3032124A1/en active Pending
- 2017-07-28 MX MX2019001084A patent/MX2019001084A/es unknown
- 2017-07-28 SG SG11201900738YA patent/SG11201900738YA/en unknown
- 2017-07-28 EP EP17754224.8A patent/EP3491014B1/en active Active
- 2017-07-28 DK DK17754224.8T patent/DK3491014T5/da active
- 2017-07-28 NZ NZ751010A patent/NZ751010A/en unknown
- 2017-07-28 US US15/662,689 patent/US10266582B2/en active Active
- 2017-07-28 KR KR1020197001965A patent/KR102661616B1/ko active Active
- 2017-07-28 KR KR1020247005755A patent/KR20240027874A/ko not_active Ceased
- 2017-07-28 WO PCT/US2017/044321 patent/WO2018022967A1/en not_active Ceased
-
2019
- 2019-01-25 MX MX2024013403A patent/MX2024013403A/es unknown
- 2019-01-27 IL IL264473A patent/IL264473A/en unknown
- 2019-03-15 US US16/354,563 patent/US10562953B2/en active Active
-
2020
- 2020-01-03 US US16/733,663 patent/US11155598B2/en not_active Expired - Fee Related
-
2021
- 2021-09-23 US US17/483,047 patent/US20220073589A1/en not_active Abandoned
-
2023
- 2023-02-10 JP JP2023019464A patent/JP2023071704A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017302611A1 (en) | 2019-03-14 |
| US10266582B2 (en) | 2019-04-23 |
| DK3491014T3 (da) | 2023-05-30 |
| EP3491014B1 (en) | 2023-04-05 |
| CN109563516B (zh) | 2023-10-27 |
| US11155598B2 (en) | 2021-10-26 |
| KR102661616B1 (ko) | 2024-04-30 |
| CA3032124A1 (en) | 2018-02-01 |
| WO2018022967A1 (en) | 2018-02-01 |
| CN109563516A (zh) | 2019-04-02 |
| EP4230648A3 (en) | 2023-10-18 |
| US20190202891A1 (en) | 2019-07-04 |
| US20200231651A1 (en) | 2020-07-23 |
| JP2023071704A (ja) | 2023-05-23 |
| US10562953B2 (en) | 2020-02-18 |
| EP3491014A1 (en) | 2019-06-05 |
| KR20190034532A (ko) | 2019-04-02 |
| AU2017302611B2 (en) | 2021-12-09 |
| IL264473A (en) | 2019-02-28 |
| KR20240027874A (ko) | 2024-03-04 |
| SG11201900738YA (en) | 2019-02-27 |
| JP2019527229A (ja) | 2019-09-26 |
| MX2024013403A (es) | 2024-12-06 |
| US20220073589A1 (en) | 2022-03-10 |
| DK3491014T5 (da) | 2024-09-02 |
| MX2019001084A (es) | 2019-06-10 |
| JP7556688B2 (ja) | 2024-09-26 |
| US20180030114A1 (en) | 2018-02-01 |
| EP4230648A2 (en) | 2023-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024013403A (es) | Variantes de gpr156 y usos de estas | |
| PH12018502361B1 (en) | Gdf15 fusion proteins and uses thereof | |
| PH12019500596B1 (en) | Recombinant binding proteins and their use | |
| PH12019500209A1 (en) | Methods and compositions for gene expression in plants | |
| SG10201906673WA (en) | Artificial nucleic acid molecules | |
| MY192481A (en) | Factor viii chimeric proteins and uses thereof | |
| EP3752191A4 (en) | NON-VIRAL DNA VECTORS AND ASSOCIATED USES FOR THE PRODUCTION OF ANTIBODIES AND FUSION PROTEINS | |
| MX2018011425A (es) | Construcciones de anticuerpos de adn y método para utilizarlas. | |
| HK1243958A1 (zh) | 核酸构建体 | |
| PH12015502849B1 (en) | Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers | |
| JP2019500414A5 (enExample) | ||
| MX382218B (es) | Variantes de lipasa y polinucleotidos que las codifican. | |
| MX386295B (es) | Mutante cd200 y sus usos | |
| MX2017005467A (es) | Polipéptidos de fusión de serpina y métodos para utilizar los mismos. | |
| NZ752941A (en) | Frataxin expression constructs | |
| NZ729735A (en) | Biosensor based on gβυ-interacting proteins to monitor g-protein activation | |
| PE20170941A1 (es) | Genes de tolerancia a herbicidas y metodos para usar los mismos | |
| NZ724196A (en) | Uti fusion proteins | |
| BR112017022076A2 (pt) | fusões de mesotelina-variante iii de receptor de fator de crescimento epidérmico e métodos de uso das mesmas | |
| MX2015009867A (es) | Mutantes del factor x. | |
| MX2015006599A (es) | Secuencias de ácidos desoxirribonucleicos sintéticos y proteinas recombinantes heterólogas de la hemaglutinina del virus influenza expresadas en cloroplasto de chlamydomonas reinhardtii y su uso en vacunas. | |
| WO2015132397A3 (en) | Mitochondrial preproteins as markers for alzheimer's disease | |
| NZ762152A (en) | Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof | |
| EA201990955A1 (ru) | Разработка капсидов aav | |
| MX2017005644A (es) | Variantes de antigeno trypanosoma cruzi jl7 recombinante y su uso para detectar la enfermedad de chagas. |